Claims for Patent: 8,535,714

Summary for Patent: 8,535,714

Title:	Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
Abstract:	Compositions, systems and methods for administration of small volume sufentanil drug dosage forms via the oral transmucosal route of a subject for treatment of pain.
Inventor(s):	Palmer; Pamela (San Francisco, CA), Schreck; Thomas (Portola Valley, CA), Hamel; Lawrence (Pacific Grove, CA), Tzannis; Stelio (Petaluma, CA), Poutiatine; Andrew (Mill Valley, CA)
Assignee:	AcelRx Pharmaceuticals, Inc. (Redwood City, CA)
Application Number:	13/276,165
Patent Claims:	1. A tablet comprising: about 5 to about 200 .mu.g sufentanil or pharmaceutically acceptable salts thereof (expressed as the free base of sufentanil), 60-95 wt % of one or more bulking agents, 1-5 wt % of one or more hydrogel forming excipients, and 1-10 wt % of one or more lubricants, wherein: said tablet has a volume less than about 30 .mu.L, and when said tablet is adhered to the oral mucosa of a patient during the period of drug delivery: a) at least 55% of the total amount of sufentanil in the tablet is delivered via the oral transmucosal route; b) at least 90% of the total amount of sufentanil delivered to the patient, as measured by plasma concentration, is delivered via the oral transmucosal route; c) said tablet provides a mean T.sub.max of about 15 minutes to about 80 minutes; d) said tablet provides a mean T.sub.max with a coefficient of variation of less than 40%; and e) said tablet provides a dose-normalized mean C.sub.max of about 1.59-2.75 pg/mL per meg dosed. 2. The tablet of claim 1, wherein said tablet has a volume of less than about 10 .mu.L. 3. The tablet of claim 1 wherein said one or more bulking agents are selected from the group consisting of mannitol, di-calcium phosphate, and combinations thereof. 4. The tablet of claim 1, wherein said one or more hydrogel forming excipients is hydroxypropylmethylcellulose. 5. The tablet of claim 1, wherein said lubricant is selected from the group consisting of stearic acid, magnesium stearate, and combinations thereof. 6. The tablet of claim 1, wherein: wherein said one or more bulking agents are selected from the group consisting of mannitol, di-calcium phosphate, and combinations thereof, said one or more hydrogel forming excipients is hydroxypropylmethylcellulose, and said lubricant is selected from the group consisting of stearic acid, magnesium stearate, and combinations thereof. 7. The tablet of claim 1, wherein the amount of sufentanil or pharmaceutically acceptable salts thereof is about 5 .mu.g, 10 .mu.g, 15 .mu.g, 20 .mu.g, 30 .mu.g, 40 .mu.g, 50 .mu.g, 60 .mu.g, 70 .mu.g, 80 .mu.g, 100 .mu.g or 120 .mu.g (expressed as the free base of sufentanil). 8. The tablet of claim 7, wherein the amount of sufentanil or pharmaceutically acceptable salts thereof is about 15 .mu.g (expressed as the free base of sufentanil). 9. The tablet of claim 7, wherein the amount of sufentanil or pharmaceutically acceptable salts thereof is about 20 .mu.g (expressed as the free base of sufentanil). 10. The tablet of claim 7, wherein the amount of sufentanil or pharmaceutically acceptable salts thereof is about 30 .mu.g (expressed as the free base of sufentanil). 11. The tablet of claim 1, wherein after administration of said tablet to said subject, said tablet provides a mean T.sub.max range of from about 30 minutes to about 70 minutes. 12. The tablet of claim 1, wherein after administration of said tablet to said subject, said tablet provides a mean T.sub.max range of from about 40 minutes to about 55 minutes. 13. The tablet of claim 1, wherein after administration of said tablet to said subject, said tablet provides a mean T.sub.max range of from about 35 minutes to about 60 minutes. 14. The tablet of claim 1, wherein after administration of said tablet to said subject, said tablet provides a mean T.sub.max with a coefficient of variation of less than 30%. 15. The tablet of claim 1, wherein after administration of said tablet to said subject, at least 60% of the total amount of drug in said tablet is absorbed via the oral transmucosal route. 16. The tablet of claim 1, wherein after administration of said tablet to said subject, at least 70% of the total amount of drug in said tablet is absorbed via the oral transmucosal route. 17. The tablet of claim 1, wherein after administration of said tablet to said subject, at least 95% of the sufentanil delivered to the patient, as measured by plasma concentration, is delivered via the oral transmucosal route. 18. A method of treating pain, comprising administering the tablet of claim 1 to a patient in need thereof. 19. The method of claim 18, wherein said administering is by adhering said tablet to the sublingual membrane of said patient. 20. The method of claim 18, wherein said tablet has a volume of less than about 10 .mu.L. 21. The method of claim 18, wherein said tablet is administered using a device. 22. A method of treating pain, comprising administering the tablet of claim 6 to a patient in need thereof. 23. A method of treating pain, comprising administering the tablet of claim 8 to a patient in need thereof. 24. The method of claim 23, wherein said tablet has a volume of less than about 10 .mu.L. 25. The method of claim 23, wherein said tablet is administered using a device.